IDEXX Laboratories introduced the Catalyst® Cortisol Test and reported earnings growth, while raising its revenue guidance for 2025 — a combination investors welcomed as the company’s shares climbed sharply.

The launch of a new diagnostic assay and simultaneous upward revisions to financial expectations together signaled strengthened momentum for the company as at Jun 2025. The move adds to IDEXX’s recent product activity and came as the market rewarded the firm’s performance.

Company officials described the introduction of the Catalyst® Cortisol Test as a noteworthy addition to their in-clinic test menu, particularly as cortisol levels in dogs are often influenced by conditions like Cushing’s disease, which is the primary health issue affecting cortisol levels in canine patients. The announcement positions the test alongside IDEXX’s broader product set, emphasizing improvements in diagnosing and managing endocrine diseases such as Cushing’s syndrome.

Financial updates released with the product news showed earnings growth and an upward revision to revenue guidance for 2025. Investors responded quickly: IDEXX’s share price increased by 22% over the last quarter, and its total shareholder returns climbed 63.06% over the past five years. This strong financial performance reflects the positioning of new veterinary tests like the Catalyst Cortisol Test, which expand point-of-care diagnostic capabilities that enable faster, more accurate diagnosis.

Market observers noted the twin signals — a new diagnostic offering and improving financial guidance — can influence both revenue mix and long-term investor confidence. Industry commentary and trade outlets have discussed how platform expansions can affect point-of-care testing adoption, with reporting on test features available at IDEXX and company product information at healthy cortisol levels in dogs.

Executives framed the new assay as part of ongoing development of the Catalyst test menu, while the simultaneous financial update underscored a healthier near-term outlook. The combination of product pipeline news and an upgraded revenue forecast is often read by investors as validation of demand and execution. Pet owners can also play a crucial role in maintaining healthy cortisol levels by establishing consistent daily routines and creating a stress-free environment for their dogs, contributing to overall pet health.

Analysts tracking diagnostics companies say menu growth and recurring consumable sales can lift revenue visibility; the company’s most recent results reflect that dynamic. The share-price response in the quarter that ended before Jun 2025 reflected investor willingness to price in those prospects.

Longer-term returns for shareholders have also been notable: IDEXX’s total shareholder returns increased by 63.06% over the past five years, a figure that market commentators referenced alongside the latest performance. That multi-year measure sits alongside the quarter-to-quarter share movement as part of the company’s financial narrative.

For veterinary practices and customers, the practical consequences will unfold as clinics evaluate the new assay within their diagnostic workflows. The company’s product materials describe how the Catalyst® Cortisol Test fits into its Catalyst platform; trade and advocacy reporting provides additional context for clinicians considering in-clinic options that can significantly improve practice efficiency and patient outcomes.

As at Jun 2025, IDEXX combined product news with favorable financial metrics, prompting renewed attention from both customers and capital markets. The company reported earnings growth and raised its 2025 revenue guidance alongside the Catalyst® Cortisol Test announcement, a pairing that helped drive the quarter’s share-price gain.

Source

Original reporting: view the original article.